Heart failure with preserved ejection fraction: Diastolic heart failure;Hartfalen met gepreserveerde ejectiefractie

Nederlands Tijdschrift voor Geneeskunde

Volumn 156, Issue 45, 2012, Pages

  Rutten, Frans H ^a   Cramer, Maarten Jan M ^a   Paulus, Walter J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIASTOLIC HEART FAILURE; HEART EJECTION FRACTION; AGING; FEMALE; HEART STROKE VOLUME; HUMAN; MALE; MORTALITY; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE;

AGING; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; MALE; PROGNOSIS; RISK FACTORS; SEX FACTORS; STROKE VOLUME;

EID: 84872018084     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Smulders YM, Stehouwer CDA, Bronzwaer JGF, Kamp O. Diastolisch hartfalen. Ned Tijdschr Geneeskd. 2003;147:2467-70 NTvGMedline.
2. Borbély A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-81.
3. Van Heerebeek L, Borbély A, Niessen HWM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-73.
4. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137-46.
5. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-9.
6. Van Heerebeek L, Hamdani N, Handoko L, et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis,advanced glcation end products,and myocyte resting tension. Circulation. 2008;117:43-51.
7. Paulus WJ. Culprit mechanism(s) for exercise intolerance in heart failure with normal ejection fraction. J Am Coll Cardiol. 2010;56:864-6.
8. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787-847.
9. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure? A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction (HFNEF) by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-50.
10. Hogg K, Swedberg K, McMurray JJV. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317-27.
11. Steinberg BA, Zhao X, Heidenreich PA, et al; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes. Circulation. 2012;126:65-75.
12. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-9.
13. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25:1614-9.
14. Van Jaarsveld CH, Ranchor AV, Kempen GI, Coyne JC, van Veldhuisen DJ, Sanderman R. Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival. Eur J Heart Fail. 2006;8:23-30.
15. Rutten FH, Cramer MJM, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887-94.
16. Martos R, Baugh J, Ledwidge M, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-7.
17. Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodeling indentify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 2011;13:1087-95.
18. Franssen C, Paulus WJ. The future diagnosis of heart failure with normal ejection fraction: less imaging, more biomarkers? Eur J Heart Fail. 2011;13:1043-5.
19. De Boer Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-8.
20. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;22:107-33.
21. Tschöpe C, Paulus WJ. Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation. 2009;120:810-20.
22. Lim TK, Dwivedi G, Hayat S, Majumdar S, Senior R. Independent value of left atrial volume index for the prediction of mortality in patients with suspected heart failure referred from the community. Heart. 2009;95:1172-8.
23. Paulus WJ, van Ballegoij JJM. Treatment of heart failure with normal ejection fraction: An inconvenient truth! J Am Coll Cardiol. 2010;55:526-37.
24. Paulus WJ. Novel strategies in diastolic heart failure. Heart. 2010;96:1147-53.
25. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162:966-72.e10.
26. Edelmann F, Schmidt AG, Gelbrich G, et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a doubleblind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail. 2010;12:874-82.
27. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357-63.
28. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.
29. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. Tognoni G for the Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-9.
30. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:415-26.
31. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, er al.; on behalf of the CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33:2290-6.
32. Kitzman DW. Exercise training in heart failure with preserved ejection fraction: beyond proof-of-concept. J Am Coll Cardiol. 2011;58:1792-4.